Bristol Myers Squibb Announces New Three-Year Results From POETYK PSO Long-Term Extension Trial Of Sotyktu (Deucravacitinib) Treatment In Adult Patients With Moderate-to-severe Plaque Psoriasis
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced new three-year results from the POETYK PSO long-term extension trial of Sotyktu (Deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. The clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment. Sotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any new safety signals.
October 11, 2023 | 10:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's Sotyktu shows positive long-term results in a trial for plaque psoriasis, which could potentially boost the company's reputation and sales in the future.
The positive results from the long-term trial of Sotyktu indicate the drug's effectiveness and safety, which could lead to increased demand and sales. This could potentially have a positive impact on Bristol Myers Squibb's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100